Nanotechnology-Based Cancer Vaccine.
Nanotechnology offers invaluable tools to tailor cancer vaccines in order to generate robust antitumor immune response. Among the types of vehicles for cancer vaccines, nanoparticles (NPs) are easier to produce with better scalability. Several nanostructures have been discussed in literature as potential delivery systems for cancer antigens. Here, we focus on polymeric NPs fabricated from poly(D,L-lactic-co-glycolic) acid (PLGA). We describe how to prepare and characterize such NPs loaded with ovalbumin (OVA) antigen and immune adjuvant monophosphoryl lipid A (MPLA). We further describe methods to test the immune efficacy of such NPs in vitro and in vivo.
Nanomedicine Research Unit, Department of Pharmaceutics, College of Pharmacy, King Saud University, 2457, Riyadh, 11451, Saudi Arabia. aalshamsan@ksu.edu.sa.|King Abdullah Institute for Nanotechnology, King Saud University, 2455, Riyadh, 11451, Saudi Arabia. aalshamsan@ksu.edu.sa.
Aws
A
Alshamsan
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy; D019344:Lactic Acid / Q000737:chemistry; D008213:Lymphocyte Activation / Q000276:immunology; D008546:Melanoma, Experimental; D053758:Nanoparticles / Q000737:chemistry / Q000648:ultrastructure; D036103:Nanotechnology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D010047:Ovalbumin / Q000737:chemistry / Q000276:immunology; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D014611:Vaccination
D019496:Cancer Vaccines; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D010047:Ovalbumin
Cancer vaccine; Dendritic cell (DC); Immunotherapy; Nanoparticle (NPs); Poly(D,L-lactic-co-glycolic) acid (PLGA)